发现和优化isoliquiritigenin作为一个与死亡相关的蛋白激酶1抑制剂
Takeshi Yokoyama1, Kotono Hisatomi2, Saki Oshima2
1Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0914, Japan.
European journal of medicinal chemistry
|September 7, 2024
概括
天然化合物异氧化基因因及其基衍生物抑制死亡相关蛋白激酶1 (DAPK1). 这些化合物显示出阿尔茨海默氏症的潜力.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 神经科学是一个神经科学.
背景情况:
- 死亡相关蛋白激酶1 (DAPK1) 是一种氨酸/氨酸激酶.
- DAPK1抑制可能有利于阿尔茨海默病和脑缺血治疗.
研究的目的:
- 为了研究异基原蛋白作为DAPK1抑制剂.
- 为了合成和评估用于增强DAPK1抑制的素衍生物.
主要方法:
- 在体外酶抑制测定.
- 石墨烯衍生物的合成.
- 对DAPK1抑制剂复合物的晶体结构分析.
主要成果:
- 伊索利基基因因以一种与ATP竞争的方式抑制DAPK1.
- ,和衍生物显示出强大的DAPK1抑制和结合.
- 晶体结构揭示了DAPK1疏水口袋中的素原子相互作用.
结论:
- 化石是有效的DAPK1抑制剂.
- 衍生物呈现出显著的体贡献,表明治疗潜力.
- 这些发现支持开发用于神经疾病的新型DAPK1抑制剂.
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


